GILGAMESH PHARMACEUTICALS Trademark

Trademark Overview

On Friday, August 2, 2019, a trademark application was filed for GILGAMESH PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the GILGAMESH PHARMACEUTICALS trademark a serial number of 88563244. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 20, 2023. This trademark is owned by GILGAMESH PHARMACEUTICALS, INC.. The GILGAMESH PHARMACEUTICALS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals, namely, pharmaceutical and drugs preparations and substances in the field of neuroscience for use in the treatment and therapy of psychiatric disorders, depression disorders, substance use, substance abuse, anxiety disorders, cognitive disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bipolar disorders, eating disorders, pain, and longevity; Diagnostic biomarker reagents for pharmaceutical and medical purposes; predictive biomarker reagents for pharmaceuticals and drugs in the field of neuroscience for use in the treatment and therapy of psychiatric disorders, depression disorders, substance use, substance abuse, anxiety disorders, cognitive disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bipolar disorders, eating disorders, pain, and longevity
gilgamesh pharmaceuticals

General Information

Serial Number88563244
Word MarkGILGAMESH PHARMACEUTICALS
Filing DateFriday, August 2, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 20, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 17, 2019

Trademark Statements

Goods and ServicesPharmaceuticals, namely, pharmaceutical and drugs preparations and substances in the field of neuroscience for use in the treatment and therapy of psychiatric disorders, depression disorders, substance use, substance abuse, anxiety disorders, cognitive disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bipolar disorders, eating disorders, pain, and longevity; Diagnostic biomarker reagents for pharmaceutical and medical purposes; predictive biomarker reagents for pharmaceuticals and drugs in the field of neuroscience for use in the treatment and therapy of psychiatric disorders, depression disorders, substance use, substance abuse, anxiety disorders, cognitive disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bipolar disorders, eating disorders, pain, and longevity
Disclaimer with Predetermined Text"PHARMACEUTICALS"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, August 21, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGILGAMESH PHARMACEUTICALS, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10003
Party NameGILGAMESH PHARMACEUTICALS, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10003

Trademark Events

Event DateEvent Description
Monday, March 20, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 20, 2023ABANDONMENT - NO USE STATEMENT FILED
Thursday, July 28, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 27, 2022SOU EXTENSION 5 GRANTED
Monday, July 11, 2022SOU EXTENSION 5 FILED
Wednesday, July 27, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, July 11, 2022SOU TEAS EXTENSION RECEIVED
Friday, January 7, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 5, 2022SOU EXTENSION 4 GRANTED
Wednesday, January 5, 2022SOU EXTENSION 4 FILED
Wednesday, January 5, 2022SOU TEAS EXTENSION RECEIVED
Thursday, July 15, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 13, 2021SOU EXTENSION 3 GRANTED
Tuesday, July 13, 2021SOU EXTENSION 3 FILED
Tuesday, July 13, 2021SOU TEAS EXTENSION RECEIVED
Wednesday, January 13, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 11, 2021SOU EXTENSION 2 GRANTED
Monday, January 11, 2021SOU EXTENSION 2 FILED
Monday, January 11, 2021SOU TEAS EXTENSION RECEIVED
Friday, July 17, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 15, 2020SOU EXTENSION 1 GRANTED
Wednesday, July 15, 2020SOU EXTENSION 1 FILED
Wednesday, July 15, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, February 11, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 17, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 17, 2019PUBLISHED FOR OPPOSITION
Wednesday, November 27, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 12, 2019ASSIGNED TO LIE
Wednesday, November 6, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 6, 2019EXAMINER'S AMENDMENT ENTERED
Wednesday, November 6, 2019NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, November 6, 2019EXAMINERS AMENDMENT E-MAILED
Wednesday, November 6, 2019EXAMINERS AMENDMENT -WRITTEN
Wednesday, November 6, 2019PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Tuesday, November 5, 2019PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Tuesday, November 5, 2019TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, November 1, 2019ASSIGNED TO EXAMINER
Wednesday, August 21, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 6, 2019NEW APPLICATION ENTERED

Related Keywords

pharmaceuticals gilgamesh disorders disorder substance traumatic post obsessive compulsive stress ptsd biomarker